More than 45 organizations, including the AHA, today encouraged members of the Senate Judiciary Committee to support the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974), which the panel is expected to consider next week. The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “It is a highly-targeted remedy that will end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs,” the organizations said in a letter to committee leaders. “The Congressional Budget Office has estimated that enacting the CREATES Act would save $3.8 billion over 10 years. We sincerely thank you and your colleagues who have supported the CREATES Act, and we encourage all members of the Committee to vote in favor of the bill.” 

Related News Articles

Headline
The House Budget Committee May 18 advanced the fiscal year 2025 budget reconciliation bill by a 17-16 vote along party lines, as four Republicans who…
Headline
The House Energy and Commerce Committee today advanced by a 30-24 vote along party lines its portion of the fiscal year 2025 reconciliation bill following a…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 14 testified on President Trump’s discretionary budget proposal for fiscal year…
Headline
The House Ways and Means Committee today advanced its portion of the fiscal year 2025 reconciliation bill by a 26-19 vote along party lines, following an hours…
Headline
The House Energy and Commerce Committee May 13 began to mark up its portion of the fiscal year 2025 reconciliation bill. The committee has been instructed to…
Headline
The House Ways and Means Committee May 13 began to mark up its portion of the fiscal year 2025 reconciliation bill, with some proposals impacting the health…